Your SlideShare is downloading. ×
Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases

41

Published on

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. …

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related.

There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7 guidelines were revised to include a greater focus on involving more geriatric patients in drug trials.

View Full Report With Complete TOC at http://www.researchmoz.us/geriatric-medicine-development-carving-out-new-opportunities-to-treat-age-related-diseases-report.html

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
41
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related. There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7 guidelines were revised to include a greater focus on involving more geriatric patients in drug trials. Scope Reviews the current regulatory landscape and helps sponsors to understand the potential impact of recent guidelines. Assesses the barriers to entry in geriatric medicines and identifies potential ways to overcome them and improve clinical decision making. Evaluates the importance of establishing Target Quality Product Profiles (TQPP) to help sponsors determine the target patient population earlier on in drug development. Identifies treatment gaps and commercial opportunities based on primary care real-time data and KOL insights. Analyses different strategies to develop age-appropriate medicines in niche therapeutic fields and discusses methods to encourage the smarter prescription of medicines. Key Reasons to Purchase Utilize the insights from this study to analyze the barriers facing the geriatrics market Understand the impact of drug development in this market now and in the future Find out why regulators are paying more attention to unnecessary “exclusion criteria” and encouraging the inclusion of older people to ensure trials are age-appropriate and more representative of the real world setting. Assess the opportunities available for companies to develop age-appropriate dosages and formulations for existing drug classes that are currently widely associated with ADEs in the elderly as well as new therapeutic prospects. table Of Content executive Summary methodology geriatric Medicines: An Overview emerging Issues unmet Clinical Needs current Landscape regulatory Environment political Will For Change strategic Considerations For Developing Geriatric Medicines barriers To Developing Geriatric Drugs clinical Trial Considerations “big Data’s” Role In Identifying Treatment Gaps And Commercial Opportunities raising Physician And Patient Awareness commercial Opportunities To Address The Treatment Gap improving Existing Therapies new Therapeutic Opportunities appendix ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases

×